Dr. Jana Jenquin, a post-doctoral fellow in the Berglund, has been award a post-doctoral fellowship award from Myotonic, (formerly MDF) to support her research on finding small molecules with therapeutic potential to treat Myotonic Dystrophy.

The goal of the first two aims of Dr. Jenquin’s study “Improving the activity of diamidines for potential therapeutic use for patients with myotonic dystrophy types 1 and 2” is to characterize our current lead small molecule by assessing how well, and by what mechanism, it rescues DM-associated molecular markers in DM1 and DM2 cell and animal models. The third aim of the study is to synthesize more compounds related to the lead compound with an emphasis on compounds predicted to cross the blood brain barrier to potentially address the cognitive symptoms associated with DM and continue to improve these compounds as potential therapeutics. The goal of the study is to get the best in class of these compounds into clinical trials for DM1 and DM2 to help patients and their families.

Thank you to Myotonic for their support of Jana’s research!

Go Back to Top ↑